Price Don’t Lie: What’s Next for Kite Pharma Inc After Today’s Huge Increase?

Price Don't Lie: What's Next for Kite Pharma Inc After Today's Huge Increase?

The stock of Kite Pharma Inc (NASDAQ:KITE) is a huge mover today! The stock increased 7.00% or $2.99 during the last trading session, hitting $45.69. About 1.96M shares traded hands or 60.66% up from the average. Kite Pharma Inc (NASDAQ:KITE) has declined 14.65% since April 5, 2016 and is downtrending. It has underperformed by 16.61% the S&P500.
The move comes after 9 months positive chart setup for the $2.15 billion company. It was reported on Nov, 7 by Barchart.com. We have $70.36 PT which if reached, will make NASDAQ:KITE worth $1.16 billion more.

Analysts await Kite Pharma Inc (NASDAQ:KITE) to report earnings on November, 10. They expect $-1.66 EPS, down 163.49% or $1.03 from last year’s $-0.63 per share. After $-1.31 actual EPS reported by Kite Pharma Inc for the previous quarter, Wall Street now forecasts 26.72% negative EPS growth.

Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage

Out of 9 analysts covering Kite Pharma (NASDAQ:KITE), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Kite Pharma has been the topic of 22 analyst reports since August 4, 2015 according to StockzIntelligence Inc. Barclays Capital initiated it with “Equal-Weight” rating and $58 target price in Wednesday, July 6 report. The stock of Kite Pharma Inc (NASDAQ:KITE) earned “Buy” rating by Citigroup on Thursday, February 25. The company was initiated on Wednesday, November 18 by Goldman Sachs. The company was maintained on Friday, August 14 by Guggenheim. Standpoint Research initiated the shares of KITE in a report on Tuesday, August 18 with “Buy” rating. The rating was maintained by FBR Capital with “Mkt Perform” on Tuesday, December 8. The rating was maintained by Mizuho with “Buy” on Tuesday, May 10. The rating was downgraded by Standpoint Research to “Hold” on Friday, November 13. The firm has “Outperform” rating by FBR Capital given on Tuesday, January 19. On Tuesday, December 15 the stock rating was upgraded by Standpoint Research to “Buy”.

According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”

Insitutional Activity: The institutional sentiment increased to 1.57 in 2016 Q2. Its up 0.38, from 1.19 in 2016Q1. The ratio improved, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.
Cap Guardian Trust, a California-based fund reported 450,200 shares. Creative Planning holds 0.01% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 20,215 shares. Spot Trading Limited Liability accumulated 2,133 shares or 0% of the stock. Nicholas Inv Limited Partnership last reported 36,897 shares in the company. Price T Rowe Associate Md holds 239,742 shares or 0% of its portfolio. Blackrock Investment Mgmt Ltd Liability Corporation has 146,226 shares for 0.01% of their US portfolio. Columbia Partners L L C Inv Mngmt has invested 0.26% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Moreover, Manufacturers Life Ins The has 0% invested in Kite Pharma Inc (NASDAQ:KITE) for 26,813 shares. Commercial Bank Of Montreal Can accumulated 0% or 6,405 shares. Amalgamated Savings Bank has 4,138 shares for 0.01% of their US portfolio. Capital World last reported 0.02% of its portfolio in the stock. Interest Invsts, a California-based fund reported 724,700 shares. Deutsche State Bank Ag has 0% invested in the company for 136,093 shares. Guggenheim Capital Limited Liability Co has 70,372 shares for 0.01% of their US portfolio. Moreover, Vanguard Group has 0.01% invested in Kite Pharma Inc (NASDAQ:KITE) for 2.94 million shares.

Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 9 selling transactions for $2.93 million net activity. Wiezorek Jeffrey also sold $87,362 worth of Kite Pharma Inc (NASDAQ:KITE) on Thursday, September 1. Another trade for 10,000 shares valued at $509,350 was sold by BUTITTA CYNTHIA M. 14,000 shares with value of $812,581 were sold by DOUMANI ROY on Monday, June 6.

More notable recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Seekingalpha.com which released: “Kite Pharma: So Much Promise, So Many Questions” on November 07, 2016, also Businesswire.com with their article: “Kite Pharma to Report Third Quarter 2016 Financial Results on November 9, 2016” published on November 02, 2016, Forbes.com published: “Kite Pharma Enters Oversold Territory (KITE)” on October 19, 2016. More interesting news about Kite Pharma Inc (NASDAQ:KITE) were released by: Businesswire.com and their article: “Kite Pharma to Present KTE-C19 Data from Interim Analysis of the ZUMA-1 …” published on November 03, 2016 as well as Zacks.com‘s news article titled: “Will Kite Pharma (KITE) Stock Surprise Post Q3 Earnings?” with publication date: November 04, 2016.

KITE Company Profile

Campello Bancorp, Inc. is a shell company. As of April 30, 2009, the Company had no assets or operations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment